Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Current Oncology Reports|August 23, 2024
How to Identify and Manage High-Risk Smoldering Multiple MyelomaTarek H MouhieddineTargeted Oncology|June 30, 2022
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple MyelomaBruno Almeida Costa, Tarek H Mouhieddine, Joshua RichterSeminars in Hematology|January 29, 2025
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies aheadTarek H Mouhieddine, Bruno Almeida Costa, Joshua RichterBest Practice & Research. Clinical Haematology|September 7, 2025
Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interceptionTarek H Mouhieddine, Irene M Ghobrial, Omar NadeemInternational Journal of Hematology|January 5, 2020
Hemophagocytic relapsed intramedullary plasmacytomaTarek H Mouhieddine, Bart Barlogie, Julie Teruya-FeldsteinBlood|April 24, 2019
Monoclonal gammopathy of undetermined significanceTarek H Mouhieddine, Lachelle D Weeks, Irene M GhobrialTrends in Molecular Medicine|May 19, 2018
Advancements in Nanomedicine for Multiple MyelomaAlexandre Detappe, Mark Bustoros, Tarek H Mouhieddine, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Established and Novel Prognostic Biomarkers in Multiple MyelomaMark Bustoros, Tarek H Mouhieddine, Alexandre Detappe, et al.Cancers|June 18, 2020
Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after AllOliver C Lomas, Tarek H Mouhieddine, Sabrin Tahri, et al.Critical Reviews in Oncology/Hematology|May 27, 2023
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectivesBruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, et al.Pageof 6